UPDATE: On Monday, 4 July 2022, a revised version of the Core Group’s access to medicines, vaccines, and other health products resolution (A/HRC/50/L.13) was circulated. The current co-sponsors include: Argentina, Brazil, China, Ecuador,* Egypt,* India, Indonesia, Malaysia, Namibia, Nepal, Paraguay,… Continue Reading
On 24 May 2022, I delivered the following constituency statement on behalf of Knowledge Ecology International, Health Action International, Oxfam, and Public Services International on the following topic: “16.2 – Strengthening WHO preparedness for and response to health emergencies” at… Continue Reading
The announcement was made by President Biden at the Global COVID-19 Pandemic Summit. KEI Statement on the NIH/C-TAP licenses Following an earlier promise from HHS Secretary Xavier Becerra, the NIH has entered into two licenses with the WHO COVID-19 Technology… Continue Reading
28 questions for broadcast treaty May 12, 2022 Term of protection 1. The 1971 Convention for the Protection of Producers of Phonograms Against Unauthorized Duplication of Their Phonograms and The 1974 Brussels Convention Relating to the Distribution of Programme-Carrying Signals… Continue Reading
On Wednesday, 11 May 2022, Knowledge Ecology International (KEI) delivered the following statement on a proposal by the African Group for a Draft work Program on Exceptions and Limitations. Knowledge Ecology International supports the Proposal by the African Group for… Continue Reading
On Wednesday, 27 April 2022 from 14:00 CEST to 16:00 CEST, the South Centre, Knowledge Ecology International (KEI), and the Washington College of Law’s Program on Information Justice and Intellectual Property (PIJIP) will convene a workshop to prepare for the… Continue Reading
On March 18, 2022, Pfizer filed a 45 page opposition to the KEI application for a compulsory license on Paxlovid patents in the Dominican Republican. This is the Pfizer filing, and KEI’s unofficial translation. Pfizer-opposition-DR-CL-18March2022.pdf Translation-Pfizer-opposition-KEI-CL-Paxlovid-18march2022.pdf The December 3, 2021… Continue Reading
2016-Mar25-email-Re-Dir-Sig-Response-March-In-Letter 2016-Dec18-Email-Chain-Re-Reasonable-Pricing-Clauses 2016-Dec24-Email-Seeking-Help-Re-NCI-Criticism-Response 2016-Dec25-Email-Seeking-Help-NCI-Rebuttal 2016Mar30-Email-Sen-Sanders-Letter 2016Apr26-Email-Nader-Response 2016Jun27-Email-re-March-in Process 2017-Jan3-Email-Re-Help-NCI-Rebuttal 2017Jan5-Email-Regarding-Kite-License-Applicants 2017Apr24-Email-Chain-Re-Xtandi-Appeal 2017Nov20-email-helping-Allen 2017-Dec7-Email-Re-Placing-Op-Ed 2019Apr16-email-CAR T-information
In a January 31, 2022 letter to Drew Hirshfeld, the Commissioner for Patents for the USPTO, and Janet Woodcock, the Acting Commissioner of the FDA, Senator Thom Tillis provides extensive criticism of the empirical work of the group I-MAK and… Continue Reading
On 13 December 2021, the Office of United States Trade Representative (USTR) posted the following request for public comment in relation to its 2022 Special 301 Review: Identification of Countries Under Section 182 of the Trade Act of 1974 noting… Continue Reading